Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 6/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | KLK1 | P06870 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577798 | 0.88 | GAA (0.46) | CXCR3POLBMAPT | |
| SCHEMBL5577570 | 0.85 | SMN1; SMN2 (0.53) | MLLT1POLBMAPT | |
| SCHEMBL5577616 | 0.85 | KLKB1 (0.52) | CXCR3KLKB1KLK1KCNH2HRH3 | |
| SCHEMBL5577608 | 0.84 | MT-CO2 (0.45) | CXCR3KLKB1 | |
| SCHEMBL5577851 | 0.84 | CHRM3 (0.46) | CXCR3POLBTP53MAPTTHRB | |
| SCHEMBL5577690 | 0.83 | CXCR3 (0.58) | CXCR3KLKB1KLK1KCNH2HRH3 | |
| SCHEMBL5577584 | 0.82 | SCN10A (0.47) | CXCR3TP53 | |
| SCHEMBL5577527 | 0.81 | OPRM1 (0.54) | CXCR3KLKB1KLK1DRD4DRD2 | |
| SCHEMBL5577304 | 0.81 | CXCR3 (0.46) | CXCR3MLLT1 | |
| SCHEMBL5577938 | 0.80 | CXCR3 (0.44) | CXCR3MLLT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CXCR3 32/4885KLKB1 2759/4885KLK1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.